MCM
VNDA icon

Munder Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Munder Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-28,325
Closed -$352K – 682
2013
Q4 		$352K Sell
28,325
-39,891
-58% -$401K ﹤0.01% 541
2013
Q3 		$747K Hold
68,216
– – 0.01% 453
2013
Q2 		$551K Buy
+68,216
New +$459K ﹤0.01% 473

Other funds holding VNDA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Munder Capital Management's VNDA Position: Q1 2014 in Review

Munder Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2014, closing a stake of 28,325 shares — an estimated $352K sold.

Munder Capital Management first reported a position in VNDA in Q2 2013 and held it in 3 quarters. The position peaked at $747K in Q3 2013. 109 funds tracked by Wall St. Rank hold VNDA as of Q1 2014.

  • Munder Capital Management reported no remaining Vanda Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Munder Capital Management sold 28,325 Vanda Pharmaceuticals shares in Q1 2014, an estimated $352K.
  • Munder Capital Management first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Munder Capital Management's Vanda Pharmaceuticals position peaked at $747K in Q3 2013.
  • 109 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2014.

Based on Munder Capital Management's 13F filing for Q1 2014, filed 5 May 2014.